direkt zum Inhalt springen

direkt zum Hauptnavigationsmenü

Sie sind hier

TU Berlin

Page Content

Health Technology Assessment

2016

  • Henschke C, Panteli D, Perleth M, Busse R (2016): Taxonomy of Medical Devices in the Logic of Health Technology Assessment [1]
  • Panteli D, Kreis J, Busse R (2016): Considering Equity in Health Technology Assessment: An Exploratory Analysis of Agency Practices [2]
  • Fuchs S, Olberg B, Panteli D, Perleth M, Busse R (2017): HTA of medical devices: Challenges and ideas for the future from a European perspective. Health Policy. [3]
  • Fuchs S, Olberg B, Panteli D, Busse R (2016): Health Technology Assessment of medical devices in Europe: processes, methods and practices. [4]

2015

  • Henschke C, Panteli D, Perleth M, Busse R (2015): A taxonomy of medical devices in the logic of HTA. [5]
  • Panteli D, Kreis J, Busse R (2015): Considering equity in HTA: an exploratory analysis of agency practices [6]
  • Panteli D, Wittenbecher F, Busse R (2015): Medizinischer Zusatznutzen von Hämodiafiltration gegenüber Hämodialyse bezüglich Mortalität und Lebensqualität [7]

2014

  • Kreis J, Panteli D, Busse R (2014): How health technology assessment agencies address the issue of unpublished data. Int J Technol Assess Health Care 30(1): 34-43 [8]
  • Perleth M, Busse R, Gerhardus A, Gibis B, Lühmann D, Zentner A (Hrsg.) (2014): Health Technology Assessment – Konzepte, Methoden, Praxis für Wissenschaft und Entscheidungsfindung. 2. Aufl. Berlin: Medizinisch Wissenschaftliche Verlagsgesell­schaft [9]

2013

  • Kreis J, Schmidt H (2013): Public Engagement in Health Technology Assessment and Coverage Decisions. Journal of Health Politics, Policy and Law 38 (1):89-122 (DOI: 10.1215/03616878-1898812) [10]

2012

  • Kreis J, Busse R (2012): From evidence assessments to coverage decisions? The case example of glinides in Germany. Health Policy 104(1): 27-31 [11]

2010

2007

  • Angermayr L, Velasco Garrido M, Busse R (2007): Ventricular assist devices for heart failure. GMS Health Technol Assess 3: Doc10 [12]
  • Heintze C, Velasco Garrido M, Kroeger A (2007): What do community-based dengue control programmes achieve? A systematic review of published evaluations. Transactions of the Royal Society of Tropical Medicine and Hygiene (2007) 101, 317—325 [13]

2006

  • Auerbach H, Schreyögg J, Busse R (2006): Cost-effectiveness Analysis of Telemedical Devices for Pre-clinical Traffic Accident Emergency Rescue in Germany. Technology and Health Care 14(3): 189-197 [14]

2005

  • Velasco-Garrido M, Busse R (2005): Policy Brief “Health Technology Assessment – An introduction to objectives, role of evidence, and structure in Europe”. Copenhagen/ Brussels: WHO/ European Observatory on Health Systems and Policies [15]

2003

  • Gernreich NC, Gerhardus A, Velasco-Garrido M (2003): Knochen- und Knochenersatzmaterialien zur parodontalen Regeneration und zum Knochenaufbau für Implantate (Health Technology Assessment, Bd. 32). Sankt Augustin: Asgard-Verlag [16]
  • Velasco-Garrido M, Busse R (2003): Whose "wish bias"? Ann Oncol 2003;14:1154 [17]
  • Velasco-Garrido M, Busse R, Hishashage A (2003): Are disease management programmes (DMPs) effective in improving quality of care for people with chronic conditions? Copenhagen: WHO Regional Office for Europe's Health Evidence Network (HEN) [18]

2002

  • Busse R, Perleth M (2002): Health Technology Assessment in Germany. In: The Challenge of Collaboration. Proceedings of the 18th Annual Meeting of the International Society of Technology Assessment in Health Care. München: Urban & Fischer, p. 9-10 [19]

2001

  • Perleth M, Busse R (2001): Health Technology Assessment of oral anticoagulation following heart valve replacement. Eur Heart J Suppl 3: Q60-64 [20]
  • Perleth M, Busse R, Gibis B, Brand A (2001): Evaluation of preventive technologies in Germany – Case studies on mammography, prostate cancer screening and fetal ultrasound. Int J Technology Assessment Health Care 17(3): 329-337 [21]
  • Perleth M, Jakubowski E, Busse R (2001): What is "Best Practice" in Health Care? State of the Art and Perspectives in Improving the Effectiveness and Efficiency of the European Health Care Systems. Health Policy 56(3): 235-250 [22]

2000

  • Perleth M, Busse R (2000): Health technology assessment in Germany: Status, challenges, and development. Int J Technology Assessment Health Care 16(2): 412-428 [23]

1999

  • Busse R, Hoopmann M, Schwartz FW (1999): Which factors determine the use of diagnostic imaging technologies for gastrointestinal complaints in general medical practice? Int J Technology Assessment Health Care 15(4): 629-637 [24]
  • Bitzer E, Busse R, Kohlmann T, Lühmann D, Perleth M (1999): Health Technology Assessment im internationalen Kontext: Wo steht Deutschland? Z ärztliche Fortbildung Qualitätssicherung 93(1): 33-38 [25]
  • European Commission, Directorate-General for Employment, Industrial Relations and Social Affairs (ed.) (1999): “Best practice“: State of the art and perspectives in the EU for improving the effectiveness and efficiency of European health systems. Writ [26]
  • Krauth C, Busse R, Smaczny C, Ullrich G, Wagner TOF, Weber J, Welte T (1999): Kostenvergleichsanalyse der stationären und ambulanten Intervalltherapie bei erwachsenen Mukoviszidose-Patienten: Ergebnisse einer prospektiven kontrollierten Studie. Med Klini [27]
  • Perleth M, Busse R, Schwartz FW (1999): Regulation of health-related technologies in Germany. Health Policy 46(2): 105-126 [28]
  • Perleth M, Mannebach H, Busse R, Gleichmann U, Schwartz FW (1999): Cardiac catheterisation in Germany: diffusion and utilization from 1984 to 1996. Int J Technology Assessment Health Care 15(4): 756-766 [29]

To top

------ Links: ------

Zusatzinformationen / Extras

Quick Access:

Schnellnavigation zur Seite über Nummerneingabe

Copyright TU Berlin 2008